Loading
A phase 1 trial of Senza5 CART5 run by Vittoria Biotherapeutics, now recruiting.
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) is a phase 1 interventional study registered as NCT06420089 by Vittoria Biotherapeutics, with 30 participants planned, started 2024-10-04. Conditions recorded: T Cell Non-Hodgkin Lymphoma. Interventions recorded: Senza5 CART5.
Shares Senza5 CART5, Vittoria Biotherapeutics and the tag pipeline.
Shares Vittoria Biotherapeutics and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/